The history of ideas has always given a prominent place to those who have grasped the many facets of reality in one organic vision. In medicine, this distinction must surely be handed to nephrology. In recent years there has been an undoubted expansion of our understanding of the role of the kidney, from a purely excretory organ to key regulator of many biological systems, and of nephrology itself growing from a simple discipline to a multidisciplinary science. A lack of similar improvements in therapy (over 50% of original renal lesions progress to chronic renal failure) does not detract from these achievements, nor does it diminish our hopes for the future.
In renal replacement therapy (RRT) the nephrologist plays a decisive role. The close relationship between dialysis and nephrology is beyond question. Nephrology has furthered the clinical use of dialysis; and dialysis had made it possible for nephrology to attain the clinical and Institutional development independence it enjoys today.
The nephrologist also plays an all important role in treating the patient who has received a renal transplant. Thus the survival afforded by both dialysis and transplantation is remarkable, especially for Living Donor Transplantation and "Early Dialysis". Survival apart, however, all other expectations (rehabilitation, quality of life, cost/benefit) have by and large been disappointing, often because of a series of "historic mistakes".
Artificial renal substitution
In dialysis, the main faults lie in thinking of the device as a "kidney", when it actually functions only as a "glomerulus"; in inadequate clinical application of this device; and in an incorrect clinical interpretation of the concept of dialysis adequacy. It is a mistake to confound technological efficacy with clinical efficacy, for whatever the technical refinements, clinical adequacy (rehabilitation from uremia) can never be achieved owing to the intrinsic limitation of the technological device. Of all the functions of the kidney it replaces only the excretory one, not the endocrine or metabolic. Quality of life is far from satisfactory; technological research seems to have outstripped our concern for the biological basis on which the technology operates; and all too often nephrologists seem to have forgotten that the first target of their multidisciplinary effort is the patient, and not the hardware.
On today's terms, dialysis has a precarious future. It affords an unsatisfactory life. Four percent of the immense current technomedical budget is spent on renal replacement therapy and 85% of this on dialysis, 15% on transplantation. Even biologically, by the canons of normal physiology, there is every reason for amazement at the survival afforded by this nonbiological new form of life. Some of its complications set in "passively" and almost inevitably (plastic particles depositing on tissues, osmotic imbalance, etc.); others, more recently discovered, are triggered by active mechanisms which uremia was wrongly thought to have suppressed.
There is a neuro-endocrine and immunological reaction to "dialysis stress", leading by complex biological paths to a kind of cellular rejection of dialysis. This is a highly complex matter that technology on its own will never solve. What is needed is a biotechnological evolution: backing technology with a biological system to reduce the "unphysiological" limitations of dialysis. This may require approaches such as bioreactors, inert membranes, hybridization or bionics. Already the breakthroughs have come from biotechnological applications such as recombinant erythropoietin.
Attempts to deantigenize dialysis membranes are another biotechnological approach. As immunological response to dialysis depends in part on the type of dialysis membrane used. Research has focused on using deantigenized material to lower this biological Evolution of nephrology response and perhaps thus reduce the incidence of complications, such as amyloidosis, that may depend on antigen stimulation by dialysis materials. Other attempts at biologizing the so-called artificial kidney and making it less unphysiological, have involved the use of hybrid-organs, in strict biological terms, a misnomer. But in the accepted extended sense, a hybrid organ is a mixed organ with cell structures superimposed on the filtering membrane. How valid the theoretical basis of the hybrid organ is in nephrology remains to be demonstrated.
Correcting the physiological shortcomings of dialysis by the bionic organ is another possible approach. Its aim is to replace all the functions of the human organ by an integrated feedback of electronics and biology. The hopes of the future lie here. Yet the project, on which we have been working for some time in our Institute, is still only in the planning phase. It is greatly complicated by the need for a close inspection of the starting assumptions: a) to define the depurative system; b) define the biological system; c) assess the two systems individually; and d) assess how they interact functionally. In our bionic project the technological parts (micro-filters and micro-reactors) are contained in micro-containers; the biological part (in future: cells genetically coded to produce hormones) is at present made up of cells of high biological potential (lymphocytes).
Computerized in vitro trials and in vivo application of individual elements in animals seem to bear out the validity of the premises of this ongoing "Bionic Project".
It is as yet impossible to predict how soon all this will become a clinical reality. Certainly not for some time. Compared with the past, the clinical evaluation of a project (from idea to actuation) takes far longer. Insulin (1921) was used immediately; the artificial kidney (1944) within 6 months; the Tenckhoff catheter (1971) after 3 years. Nowadays a project can easily take 12 years. Unfortunately, much of this delay is due to an invasive bureaucracy that smothers growth and raises the cost of eventual products astronomically.
Renal transplantation
In transplantation the present applicatory "deadlock" also stems from early mistakes such as: a) failing to foresee the extent of the demand; b) the myth of 686 controlled immunomodulation; c) the danger of donor/ recipient transmission of unknown diseases.
Pending the introduction of new drugs to enhance immunomodulation, one has the prospect of the potential clinical application of biotechnology (biocomponents, photophoresis, deantigenization, transgenization) .
The use of biotechnological products in renal medicine as a whole has in recent years undergone a steady development in four main stages:
Stage 1 refers to the clinical use of biologically active products, obtained by the recombinant DNA technique (such as erythropoietin).
Stage 2 is marked by the achievement of in situ release into the organism of pre-formed bio-synthetic products (e.g. specific antibodies).
Stage 3 concerns the use of techniques to release biosynthetic active principles, targeted at specific tissues and organs (e.g. deantigenizing the graft by immunotoxins designed to destroy passenger lymphocytes inside the graft before it is implanted in the recipient).
Stage 4, lastly, may consist in implanting bio-active substance producing cells encapsulated in biocompatible membranes. In clinical transplantation this refers above all to the implanting pancreas-islet cells in diabetic nephropathy.
The greatest problem at present, however, remains the shortage of donors. This is estimated to worsen in future (1 donor every 2,000 recipients within a few years). One solution may come from techniques of transgenization (incorporation of a human gene in an animal genome, so as to step up the immunological tolerance of the graft). Xeno-transplant is predicted to be the up-and-coming form of organ donation, destined to increase spectacularly from the year 2,000 onwards. Xeno-transplants performed to date (33 in the baboon), have tended to be unsatisfactory, chiefly because of immunological intolerance. The transgenized animal of the future may be the pig, for reason of cost and reproducibility in captivity. Thus it remains to be seen whether bionics or xeno-transplantation will become the preferred biotechnological approach for the future.
CONCLUSION
It is clear that the beauty of nephrology lies in its ramifications across the disciplines or the coexistence within it of various disciplines, which is one and the same thing. Whenever this axiom has been forgotten, the worst discrepancies have come to light between evolution of knowledge and evolution of the potential applications of knowledge.
The science of nephrology has, in the course of its history, revealed its potential, its limits and also the gift of life that dialysis and transplantation have to offer. Lines have been laid down to guarantee this therapy a future, despite our concern today over the long-term biological, clinical and social results.
What is called for is a kind of "scientific humanism", in the sense of a keener understanding of nephrology's role as the go-between with man and his rights on the one hand, and technology with its rationalism on the other. The nephrologist must never lose sight of his goal, which is man. He must be able to deal with the shifting line of demarcation between science and ethics. Whenever this line gets shifted too rapidly in the forefront of modern medicine (which includes RRT), hasty judgements may be levelled against the operator in the field. And yet the latter, on his own, has to decide: a) when to start artificial therapy without jeopardizing individual biology and hence clinical rehabilitation; b) when to "turn off" the machine so as to optimize donation time and hence also the transplant that follows; c) whether and if living donations are still to be advocated ("primum non nocere"); d) whether and if biological hybridization (e.g. xenotransplants) is ethically and clinically justified.
Thus clinical and ethical problems are tightly interwoven, in a world of sensational news and journalistic scoops. It is all too easy to end up in no man's land, between licit and illicit, known and unknown, where no precise moral, rational or religious laws exist to preserve us from "error" or "omission"; and what these precisely are depends on the angle of judgement and just where the line is drawn, at the time, between Science and Morality. Truly, what might have seemed unethical 10 years ago, may now be seen as ethical, and vice versa.
And so: if "all to all" becomes out of date, who will take the decisions?
And what policies will be followed? 
